WGS

WGS

USD

GeneDx Holdings Corp. Class A Common Stock

$139.485+4.575 (3.391%)

リアルタイム価格

Healthcare
Diagnostics & Research
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$134.910

高値

$141.750

安値

$134.000

出来高

0.68M

企業ファンダメンタルズ

時価総額

4.0B

業種

Diagnostics & Research

United States

取引統計

平均出来高

0.58M

取引所

NMS

通貨

USD

52週レンジ

安値 $55.17現在値 $139.485高値 $146

関連ニュース

Analyst Upgrades

Wells Fargo Maintains Equal-Weight on GeneDx Holdings, Raises Price Target to $140

Wells Fargo analyst Brandon Couillard maintains GeneDx Holdings with a Equal-Weight and raises the price target from $95 to $140.

もっと見る
Wells Fargo Maintains Equal-Weight on GeneDx Holdings, Raises Price Target to $140
Analyst Upgrades

Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $160

Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings with a Buy and raises the price target from $155 to $160.

もっと見る
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $160
Analyst Upgrades

Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $170

Guggenheim analyst Subbu Nambi maintains GeneDx Holdings with a Buy and raises the price target from $115 to $170.

もっと見る
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $170
Analyst Upgrades

BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $165

BTIG analyst Mark Massaro maintains GeneDx Holdings with a Buy and raises the price target from $140 to $165.

もっと見る
BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $165
BusinessWire

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

Reported third quarter 2025 revenues of $116.7 million with 65% year-over-year growth in exome and genome test revenue Accelerated exome and genome volume growth to 33% year-over-year Expanded adjusted gross

もっと見る
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
PR Newswire

GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims

Schubert Jonckheer & Kolbe LLP reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating...

Analyst Upgrades

BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $140

BTIG analyst Mark Massaro maintains GeneDx Holdings with a Buy and raises the price target from $125 to $140.